Philip Morris International declares $1.47 quarterly cash dividend
The Board of Directors of Philip Morris International (NYSE:PM) declared a regular quarterly cash dividend of $1.47 per common share, matching its previous distribution level.
Todas as matérias desta seção, das mais recentes às mais antigas — página 156 de 371.
The Board of Directors of Philip Morris International (NYSE:PM) declared a regular quarterly cash dividend of $1.47 per common share, matching its previous distribution level.
AEVEX (NYSE:AVEX) announced the delivery of a $12.3 million multi-mission DHC-6-300 Twin Otter aircraft to the Oregon Department of Forestry (ODF), providing specialized airborne data gathering capabilities just as the region enters its peak summer wildfire cycle.
WisdomTree (NYSE:WT) announced that its firm-wide assets under management reached an all-time high in May 2026, fueled by record asset volumes across its U.S., European, and Digital Asset segments, alongside the formal closing of a key international acquisition.
Hooker Furnishings (NASDAQ:HOFT) reported a return to profitability for its fiscal 2027 first quarter, driven by sharp gross margin expansion and resilient performance across its core segments, even as soft consumer demand continues to drag on top-line retail furniture sales.
Cellectis (NASDAQ:CLLS) reported highly encouraging clinical updates for its off-the-shelf, gene-edited cancer therapies, highlighting a perfect overall response rate in a target group of leukemia patients.
Vertex Pharmaceuticals (NASDAQ:VRTX) announced highly anticipated clinical data demonstrating that its CRISPR-based gene-editing therapy, CASGEVY, matches its highly successful adult profile when used in younger children.
Johnson & Johnson (NYSE:JNJ) reported positive data from a late-stage clinical trial for its drug Imaavy, strengthening its bid to secure the first regulatory approval for a rare, life-threatening autoimmune blood disorder.
Medicus Pharma (NASDAQ:MDCX) submitted an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi, seeking authorization to launch a genomics-enabled Phase 2a clinical trial evaluating its candidate Teverelix in women with symptomatic endometriosis.
Rafael Holdings (NYSE:RFL) reported its third-quarter fiscal 2026 financial results alongside a critical clinical milestone, finalizing the active clinical phase of its lead rare disease program and clearing the path for a regulatory submission later this year.
Aurora Cannabis (NASDAQ:ACB) reported record global medical cannabis net revenue and adjusted EBITDA for fiscal year 2026, capitalizing on its structural pivot toward high-margin prescription markets in Europe and Australia.
Oracle (NYSE:ORCL) reported record fourth-quarter and full-year 2026 financial results, with broad-based growth across its Cloud Infrastructure and Cloud Applications businesses.
Humacyte (NASDAQ:HUMA) announced positive top-line interim results from its V012 Phase 3 clinical trial evaluating its Acellular Tissue Engineered Vessel (ATEV) as a universally implantable conduit for hemodialysis access in female patients.
A Los Angeles County Superior Court jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $32 million to the family of a California woman who died from pleural mesothelioma, concluding that her fatal cancer was directly caused by decades of exposure to asbestos-contaminated talc in the company's iconic baby powder.
A California state court judge has denied post-trial motions by Meta Platforms (NASDAQ:META) and Google’s (NASDAQ:GOOGL) YouTube seeking a new trial, upholding a landmark jury verdict that found the tech giants liable for intentionally designing addictive features that harm the mental health of youth.
Nexalin Technology (NASDAQ:NXL) reported the successful completion of an 8-week, single-center, prospective, open-label clinical trial evaluating its proprietary 15 milliamp (mA), 77.5 Hz Deep Intracranial Frequency Stimulation (DIFS™) protocol in adults with generalized anxiety disorder and comorbid insomnia.
Eva Live (NASDAQ:GOAI), a Los Angeles-based artificial intelligence ad-tech company, announced it has signed a non-binding letter of intent (LOI) to acquire Psquared, a profitable performance-marketing agency.
Warner Music Group (NASDAQ:WMG) announced Wednesday that it is acquiring AI attribution startup Sureel AI, a company that has developed patented technology to create “AI DNA” for songs.
Comstock (NASDAQ:CHCI) announced a definitive agreement with Jericho Energy Ventures to establish a joint venture named Oklahoma AI Ventures, aiming to develop mega-scale artificial intelligence data center campuses in rural Oklahoma.
Danaher (NYSE:DHR), a global science and technology innovator, announced that it has completed the acquisition of Masimo (NASDAQ:MASI), a specialty diagnostics provider known for pulse oximetry and other patient monitoring solutions in acute care settings.
Prenetics Global (NASDAQ:PRE), the parent company of the IM8 premium health and longevity brand, reported first-quarter 2026 revenue of $36 million, with IM8 contributing $33.8 million.
HEICO (NYSE:HEI) announced that its Exxelia subsidiary has acquired a 90% stake in CalRamic Technologies, a Reno, Nevada-based manufacturer of high-voltage ceramic capacitors.
T. Rowe Price Group (NASDAQ:TROW) reported month-end assets under management (AUM) of $1.89 trillion as of May 31, 2026.
ParaZero Technologies (NASDAQ:PRZO) announced that it has secured two purchase orders in Israel for its DefendAir Net Pod system, marking a significant step in integrating its autonomous Counter-UAS technology into advanced defense platforms.
Paramount Skydance's (NASDAQ:PSKY) proposed $110 billion acquisition of Warner Bros. Discovery (NASDAQ:WBD) has come under formal scrutiny from the European Union over its financial backing from Middle Eastern sovereign wealth funds, according to a European Commission filing.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade